Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX+ACTD vs MTX in Low-Risk GTN (Score 5-6)
NCT03885388Phase 3Unknown
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of actinomycin D in gestational trophoblastic neoplasia (GTN), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Primary Complete Remission at 24 weeks. Status: unknown.
02
Drugs
actinomycin D
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT03885388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885388.